Rayno Life Science Portfolio: Another Buyout- MITI Goes for $1.16B

http://ezeta.com/index.php?option=com_content M&A Trend Picks Up Steam

click The beat goes on as Amgen agrees to buy Micromet (MITI $10.95) for $1.16B.Micromet is focused on treatment  of hematologic malignancies with its BiTE monoclonal antibody platform and has four clinical stage  product candidates. The stock was $5 on November 25 ,2011.

go Micromet was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $4.

This is beginning to feel like the biotech market of 1999.

No comments yet.

Leave a Reply